Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over

NCT06569823 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

764

Enrollment

INDUSTRY

Sponsor class

Conditions

Shingles
Herpes Zoster
Vaccine-Preventable Diseases

Interventions

BIOLOGICAL: Z-1018
BIOLOGICAL: Shingrix

Sponsor

Dynavax Technologies Corporation